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Background: The term dangerous universal blood donor refers to potential agglutination of
the  erythrocytes of non-O recipients due to plasma of an O blood group donor, which con-
tains high titers of anti-A and/or anti-B hemagglutinins. Thus, prior titration of anti-A and
anti-B hemagglutinins is recommended to prevent transfusion reactions.
Objective: The aim of this study was to estimate the frequency of dangerous universal donors
in  the blood bank of Belo Horizonte (Fundac¸ão Central de Imuno-Hematologia – Fundac¸ão
Hemominas – Minas Gerais) by determining the titers of anti-A and anti-B hemagglutinins
in  O blood group donors.
Method: A total of 400 O blood group donors were randomly selected, from March 2014 to Jan-
uary 2015. The titers of anti-A and anti-B hemagglutinins (IgM and IgG classes) were obtained
using the tube titration technique. Dangerous donors were those whose titers of anti-A or
anti-B IgM were ≥128 and/or the titers of anti-A or anti-B IgG were ≥256. Donors were char-
acterized according to gender, age and ethnicity. The hemagglutinins were characterized by
speciﬁcity (anti-A and anti-B) and antibody class (IgG and IgM).
Results: Almost one-third (30.5%) of the O blood group donors were universal dangerous.
The frequency among women was higher than that of men (p-value = 0.019; odds ratio: 1.66;
95%  conﬁdence interval: 1.08–2.56) and among young donors (18–29 years old) it was higher
than  for donors between 49 and 59 years old (p-value = 0.015; odds ratio: 3.05; 95% conﬁ-
dence interval: 1.22–7.69). There was no signiﬁcant association between dangerous universal
donors and ethnicity, agglutinin speciﬁcity or antibody class.
Conclusion: Especially platelet concentrates obtained by apheresis (that contain a substan-
tial  volume of plasma), coming from dangerous universal donors should be transfused in
isogroup recipients whenever possible in order to prevent the occurrence of transfusion
reactions.
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Introduction
Knowledge about the ABO system, from the ﬁrst exper-
iments of Karl Landsteiner established the beginning of
scientiﬁc transfusion medicine.1 Ottenberg gave a priceless
contribution to start the practice of transfusions, when he
demonstrated that the occurrence of transfusion reactions
depend on, among other factors, the titers of hemagglutinins
in donor plasma.2
It is known that anti-A and anti-B hemagglutinins are
potent IgM and IgG antibodies that bind to antigens A and B on
the surface of erythrocytes and may activate the complement
cascade resulting in acute intravascular hemolysis.3 The anti-
gens of the ABO system are expressed in erythroid precursors
from the ﬁfth or sixth week of intrauterine life. The maximum
expression of these antigens is obtained between two and four
years old.4
The term dangerous universal blood donor was ﬁrst
described in 1923 in reference to the agglutination poten-
tial of erythrocytes of non-O recipients, due to plasma of O
blood group donors that contains high titers of anti-A or anti-B
hemagglutinins.5 In the clinical practice, the term ‘dangerous’
refers to the in vivo hemolytic potential of high titers of hemag-
glutinins present in the plasma of O blood group donors. Thus,
prior titration of anti-A and anti-B hemagglutinins is recom-
mended to prevent transfusion reactions.
The aim of this study was to estimate the frequency of
dangerous universal donors in the blood bank of Belo Hori-
zonte (Fundac¸ão Centro de Hematologia e Hemoterapia de
Minas Gerais – Hemominas) by determining titers of anti-A
and anti-B hemagglutinins in O blood group donors and to
propose measures to prevent iatrogenic complications.
Method
Study  design
This study was approved by the local Ethics Committees
(Fundac¸ão Hemominas and the Universidade Federal de Minas
Gerais) and was conducted in the Immunohematology Center
of the blood bank in Belo Horizonte.
The sample calculation was made considering the num-
ber of O blood group donors in the blood bank in 2012 (34,647
donors), the prevalence of dangerous universal donors in sim-
ilar studies conducted in Brazil (average approximately 10%)
and a level of signiﬁcance of 5%. This calculation indicated
the need to analyze at least 400 samples of O blood group
donors to estimate the frequency of dangerous universal
donors.6
O blood group donors were selected randomly, accord-
ing to the following inclusion criteria: absence of irregular
antibody screening and negative hemoglobin S test results
regardless of the RhD phenotype, ethnicity, age and gender.
Exclusion criteria were O blood group donors that had any
positive test results mentioned above and those with A, B
or AB blood groups and subgroups. Samples obtained from
O blood group donors were evaluated from March 2014 to
January 2015. 2 0 1 6;3  8(3):193–198
Hemagglutinin  titration  technique
The titers of anti-A and anti-B hemagglutinins were performed
using the tube technique, which is considered standard.7
The titration of anti-A and anti-B hemagglutinins (IgM
class) was performed by serial dilutions of donor plasma col-
lected in ethylenediaminetetraacetic acid (EDTA) using saline
solution (from 1:1 until 1:1024). The last tube was kept for
further dilutions if necessary.
Then, 5% suspensions of red blood cells (A1 and B) were
added, giving a ﬁnal volume of 100 L. The tubes were incu-
bated for 15 min  at room temperature and centrifuged for
reading, in accordance with the laboratory’s norms (1000 rpm
for one minute). An agglutination reading was performed for
each tube. The titer was deﬁned as the inverse of the last dilu-
tion that produced an equivalent of 1+ agglutination. This is
characterized by a slightly agglutinated blurred background as
described in the Technical Manual of the American Associa-
tion of Blood Bank (AABB).8 When the titers of anti-A or anti-B
hemagglutinins were ≥128, donors were considered to be in
the dangerous universal group.9
For the titration of anti-A and anti-B hemagglutinins (IgG
class), the donor plasma was treated with 0.01 M dithiothreitol
(DTT – Sigma–Aldrich®) to destroy IgM class immunoglobu-
lins, so that they would not interfere with the quantiﬁcation
of IgG class hemagglutinins. Then, serial dilutions were pre-
pared with the treated plasma in saline solution [from 1:2
(DTT + plasma) until 1:1024]. The last tube was kept for fur-
ther dilutions if necessary. Then, 5% suspensions of red blood
cells (A1 and B) were added, giving a ﬁnal volume of 100 L.
The tubes were incubated for 15 min  at 37 ◦C and the erythro-
cytes were washed three times with saline solution. Coombs
monospeciﬁc IgG anti-serum (Lorne®) was added and the
tubes were centrifuged for reading in accordance with the lab-
oratory’s norms (1000 rpm for one minute). An agglutination
reading was performed for each tube. The titer was deﬁned
as the inverse of the last dilution that produced an equiv-
alent of 1+ agglutination. This is characterized by a slightly
agglutinated blurred background as described by the Techni-
cal Manual of the AABB.8 When the titers of anti-A or anti-B
hemagglutinins were ≥256, donors were considered to be in
the dangerous universal group.10
Statistical analysis was performed using the GraphPad
Prism (version 5.0) and Minitab (17th version) software. A cal-
culation of the number of samples classiﬁed as dangerous
was performed with the result expressed as a percentage
of O blood group donors. The analyses of the association
between hemagglutinin titers and gender, ethnicity and age
used the chi-square test (2). When the expected values were
≤5, Fisher’s exact test was used to verify associations. p-Values
≤0.05 were considered signiﬁcant.
Odds ratio (OR) and 95% conﬁdence intervals (95% CI) were
determined for the variables that showed any association with
the hemagglutinin titers.Results
Of the 400 samples from O blood group donors, 122 (30.5%) had
anti-A and/or anti-B hemagglutinin titers greater than or equal
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Figure 1 – Relative frequency of O blood group donors
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Figure 3 – Absolute frequencies of evaluated donors
stratiﬁed by ethnicity and classiﬁed as dangerous orlassiﬁed as dangerous and non-dangerous.
o the set cut-off points, regardless of the antibody class. In
78 samples (69.5%), the anti-A or anti-B hemagglutinin titers
ere lower than the cut-off point (Figure 1).
Of the 400 samples evaluated, 209 were from men  (52.3%)
nd 191 were from women (47.7%). Of the men, 53 (25.3%)
ere classiﬁed as dangerous universal donors and 156 (74.7%)
s non-dangerous. Of the women, 69 (36.1%) were classi-
ed as dangerous donors and 122 (63.9%) as non-dangerous.
ccording to the chi-square test, the percentage of danger-
us universal donors was signiﬁcantly higher among women
p-value = 0.019) (Figure 2).
Regarding ethnicity, of the 400 donors included in the sur-
ey, 136 declared themselves as White (34%), 54 as Black
13.5%), 208 as Mulatto (52%) and two as Asiatic (0.5%). Of the
22 donors classiﬁed as dangerous, 43 (35.2%) declared them-
elves as White, 20 (16.4%) as Black and 59 (48.4%) as Mulatto.
n applying the chi-square and Fisher’s exact tests, there was
o association between the ethnical background and being
lassiﬁed as a dangerous donor (Figure 3).
Regarding the age group, of the 400 donors included in this
urvey, 169 (42.2%) donors were between 18 and 28 years old,
16 (29.0%) were from 29 to 38 years old, 69 (17.3%) from 39
o 48 years old, 36 (9.0%) between 49 and 58 years old and
0 (2.5%) were from 59 to 69 years old. Of the 122 donors
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igure 2 – Absolute frequencies of donors stratiﬁed by
ender and classiﬁed as dangerous or non-dangerous.
Signiﬁcant difference between groups (p-value <0.05).non-dangerous.
classiﬁed as dangerous, 64 (52.4%) belonged to the 18–28
year-old age group, 32 (26.2%) to the 29–38 year-old group,
18 (14.8%) to the 39–48 year-old group, six (5.0%) to the
49–58 year-old group and two (1.6%) to the 59–69 year-old
group. On applying the chi-square test, there were no signif-
icant differences except in respect to the 18–28 year-old and
49–58 years-old groups (p-value = 0.015). For the 59–69 year-old
group, statistical analysis used the Fisher’s exact test and there
were no signiﬁcant differences compared to the other groups
(Figure 4).
Regarding the speciﬁcity of hemagglutinins (Table 1),
univariate analysis of the data revealed no signiﬁcant asso-
ciation between being classiﬁed as a dangerous universal
donor and higher anti-A or anti-B hemagglutinin titers (p-
value = 0.7468).
In respect to the antibody class (Table 2), univariate analy-
sis showed no signiﬁcant association between being classiﬁed
as a dangerous universal donor and higher IgM or IgG class
antibody titers (p-value = 0.4846).
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Figure 4 – Absolute frequency of donors stratiﬁed by age
and classiﬁed as dangerous or non-dangerous. *Signiﬁcant
difference between groups (p-value <0.05).
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Table 1 – Distribution of anti-A and anti-B agglutinins between dangerous and non-dangerous donors.
Agglutinin speciﬁcity Dangerous donor?a Total titrations p-Value
Yes No
Anti-A 88 712 800
0.7468Anti-B 84 716 800
Total titrations 172 1428 1600
Four titrations were performed for each sample: anti-A IgM, anti-B IgM, anti-A IgG and anti-B IgG.
a 1:128 dilutions was the cut-off point for IgM antibodies and 1:256 dilutions for IgG antibodies.
Table 2 – Distribution of IgM and IgG antibody classes between dangerous and non-dangerous donors.
Antibody classes Dangerous donor?a Total titrations p-Value
Yes No
IgM 76 724 800
0.4846IgG 68 732 800
Total titrations 144 1456 1600
M, an
ilutioFour titrations were performed for each sample: anti-A IgM, anti-B Ig
a 1:128 dilutions was the cut-off point for IgM antibodies and 1:256 d
Discussion
Reports of hemolytic reactions after the transfusion of blood
products due to dangerous universal donors are found in
the literature.11 The risk is directly associated to the hemag-
glutinin titer and residual volume of plasma present in the
transfused blood components.12 It is especially worrying in
platelet transfusion, knowing that the platelet concentrates
have a considerable amount of plasma, in particular those
obtained by apheresis.11
In Brazil, hemagglutinin titration is not mandatory in blood
banks. According to Ordinance 158 05/02/2016, the plasma
contained in platelet concentrates will be ABO compatible
with the recipient’s red blood cells. If this is not possible, it
is recommended that the plasma volume of the blood compo-
nent and the presence of clinically relevant anti-A and anti-B
hemagglutinins (hemolysin) is evaluated when the transfu-
sion of non-isogroup platelet concentrates is necessary.13
However, according to a recent study by Landim et al.,12 there
is no correlation between hemolysin and the risk of clinical
hemolysis or hemagglutinin titers reinforcing the importance
of analyzing hemagglutinins, which is considered the gold
standard prophylaxis against hemolysis related to plasma-
incompatible platelet transfusions.
It is worth noting that it is difﬁcult to deﬁne dangerous
universal donors with the titers because of disagreements
regarding titration techniques and the delineation of critical
limits. Many  studies use a cut-off point of 100 to clas-
sify a donor as dangerous using the microplate titration
technique.14–18 It should be noted that standardization in the
reading of agglutination intensities using this technique is
more  complex compared to the tube technique in respect to
the titer deﬁnition of the AABB Technical Manual. The titer
is given as the highest dilution that produces a macroscopic
agglutination of one cross (1+).8
This study revealed that 30.5% of O blood group donors at
the blood bank in Belo Horizonte were classiﬁed as dangerousti-A IgG and anti-B IgG.
ns for IgG antibodies.
universal donors. This result is similar to that obtained in an
Italian study (27.7%) carried out in 1977, which investigated
samples from 504 donors and performed the titrations using
the tube technique.19
In contrast, a Thai study found a frequency of 75.7% of
dangerous universal donors due to anti-A IgM antibodies and
80.0% due to anti-B IgM antibodies, while the frequencies of
high-risk donors due to anti-A IgG and anti-B IgG antibodies
were 93.0% and 95.3%, respectively. The researchers linked the
high frequency of dangerous donors to environmental factors,
differences in the composition of the intestinal microbiota,
presence of intestinal parasites, outcomes of vaccination or
exposure to other antigens. They also noted that the number
of female donors had grown in recent years, which can justify
the proportion of high-risk donors, as pregnancy is a factor
that contributes to higher anti-A and anti-B hemagglutinins.20
Note that the cut-off point adopted in this study was 64, that
is less than that in most other studies, which explains, in part,
the high number of dangerous donors.12
Two studies involving African populations that aimed to
determine the hemolytic activity of anti-A and anti-B hemag-
glutinins in O blood group donors, by investigating hemolysin
reactivity at 37 ◦C revealed that in Nigeria the frequency of
hemolytic activity was 23.2%.21 In Zimbabwe, more  than 60%
of plasma from donors had hemolytic activity and high titers
of IgG class antibodies (≥64). The researchers correlated these
ﬁndings to the characteristics of the population, such as the
high incidence of perinatal hemolytic disease and history of
previous transfusions.22
Another African study aimed to compare the hemolytic
activity of anti-A and anti-B in two racial groups, Black and
White Zimbabweans, living under similar conditions. Serum
from Black subjects showed greater hemolytic activity of anti-
A and anti-B hemagglutinins, which shows that the ethnic
background may be an important factor in the hemolytic
activity of ABO antibodies.23 However, statistical analysis of
the present study revealed no signiﬁcant correlation between
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thnicity and being classiﬁed as a dangerous universal donor,
espite the great ethnic complexity of the Brazilian popula-
ion.
In fact, high titers of hemagglutinins in plasma from O
lood group women can be explained, in part, by gestations
f fetuses with non-identical ABO blood groups. This may
xplain the higher frequency of women classiﬁed as danger-
us universal donors in this study. There is evidence that
erinatal hemolytic disease due to ABO incompatibility is
evere in the ﬁrst pregnancy; probably the second incompati-
le fetus will also be affected by the disease, which reinforces
he theory that high titers of anti-A and anti-B remain in
omen  for a long time.4,19 At the blood bank in Belo Hori-
onte, the chance of a woman being classiﬁed as a dangerous
niversal donor was 1.66 times higher than men [odds ratio
OR) = 1.66; 95% CI = 1.08–2.56].
The high percentage of people who  declared themselves
s mulatto reﬂects the great heterogeneity of the Brazilian
opulation. Brazil is considered to have one of the most
eterogeneous populations in the world resulting from the
ixing of people from different continents. In addition, the
ast territory and the displacement of different population
roups in different regions of the country has led to a con-
iderable phylogeographical heterogeneity.24 The statistical
nalysis revealed no signiﬁcant correlation between ethnic-
ty and being classiﬁed as a dangerous universal donor, which
robably reﬂects the complex ethnic categorization of the pop-
lation.
Regarding the age group, the data of this study show a sig-
iﬁcant association between young donors (18–28 years old)
nd high titers of hemagglutinins compared to older donors
49–58 years old). It is known that, in general, the production of
nti-A and anti-B hemagglutinins starts between the third and
ixth months of life. The titers of these antibodies reach peaks
etween the ages of ﬁve and ten years. After that, a progressive
ecline in the hemagglutinins is observed as the individual
ges.4 At the blood bank in Belo Horizonte, the chance of a
oung donor (18–28 years old) being classiﬁed as a dangerous
niversal donor was 3.05 times greater than 49–58 year-old
ndividuals (OR = 3.05; 95% CI = 1.22–7.69).
This study did not ﬁnd any signiﬁcant association between
he speciﬁcity of hemagglutinins and being classiﬁed as a
angerous universal donor. However, it is known that anti-
 hemagglutinin titers tend to be higher in the plasma of O
lood group individuals than anti-B hemagglutinin titers.4,25
Moreover, there was no signiﬁcant association between the
ntibody class and being classiﬁed as a dangerous universal
onor. In general, the goal of automated titration of anti-A
nd anti-B hemagglutinins is just to search for IgM antibod-
es because there is a signiﬁcant association between high
evels of anti-A and anti-B IgM and hemolysis in vitro and
ot for IgG antibodies. Thus, the titration of anti-A and anti-
 IgM antibodies is recommended to test for incompatible
latelet transfusions, especially related to female apheresis
onors.20
In Brazil, few studies have investigated the frequencies of
angerous universal donors in blood banks. In Botucatu, São
aulo, 12.8% of O blood group donors were classiﬁed as dan-
erous; 58.4% due to anti-A IgM antibodies, 14.2% due to anti-B
gM antibodies and 27.2% due to both.16 1 6;3  8(3):193–198 197
In São José dos Campos, São Paulo, a study that included
6210 samples from O blood group donors revealed a frequency
of 13.6% of dangerous universal donors due to anti-A and
anti-B IgM antibodies. However, the inﬂuence of each hemag-
glutinin was not distinguished and IgG antibodies were not
evaluated.15
Another study involving 4447 samples of O blood group
donors found frequencies of 1.2% of donors classiﬁed as dan-
gerous universal donors in Itapeva and 5.3% in Ourinhos both
in São Paulo, without distinguishing the inﬂuence of each
hemagglutinin and without assessing IgG antibodies.18
In Guarapuava, Paraná, the frequency of dangerous uni-
versal donors was 7.3% (44.4% had high titers of anti-A IgM
antibodies, 35.6% of Anti-B IgM antibodies and 20% of both).
IgG antibodies were not evaluated.17
All these studies have common characteristics: they used
the microplate titration technique after diluting the samples
in saline, adopted a titer of over 100 to classify donors as
dangerous and only evaluated the IgM antibodies, which may
explain the low frequency of donors classiﬁed as dangerous
compared to the current study. However, it is important to
remember that it is technically difﬁcult to grade the intensity
of hemagglutination using microplates.
Recent Brazilian studies employed the tube titration
technique.12,26,27 In São Paulo, Franc¸a et al.26 evaluated 603
frequent O blood group donors by apheresis or whose blood
components would be transfused in newborns; only 13% of
donors presented high titers of hemagglutinins (cut-off point
>64). The IgG antibodies were not evaluated, which may
explain the low frequency of dangerous universal donors. Var-
gas et al.,27 in Porto Alegre, Rio Grande do Sul, evaluated 610 O
blood group donors who were donating platelets by apheresis
and found a frequency of 50.7% of donors with high titers of
anti-A antibodies and 41.5% of anti-B antibodies. The method-
ology used in this study was the tube technique diluted 1:100
in saline. The results were similar to the current study, but the
IgG antibodies were not evaluated.
Some methodological differences that may inﬂuence the
results obtained in studies conducted in Brazil can be men-
tioned. These differences include performing serial dilutions
of samples or just diluting 1:100 in saline, the time of incu-
bation before reading, aspects related to the calibration of
equipment (centrifuges and pipettes) and the subjectivity of
readings. On remembering the size of Brazil, it is worth noting
that differences in the characteristics of the population might
justify the differences in frequencies of dangerous universal
donors in different studies.
Conclusion
In conclusion, platelet concentrates from dangerous univer-
sal donors, particularly those obtained by apheresis, must be
identiﬁed and when possible transfused in isogroup recipients
in order to prevent the occurrence of transfusion reactions.
The results of this study aroused the interest of Fundac¸ão
Hemominas in respect to dangerous universal donors, result-
ing in the beginning of the standardization of automated
titrations of anti-A and anti-B hemagglutinins that is eventu-
ally expected to be routine. This, undoubtedly, is an important
oter.
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step toward making transfusion therapy safer for patients who
beneﬁt from blood components from O blood group donors.
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